Mehdi Maanaoui,Rémi Lenain,Yohann Foucher,Fanny Buron,Gilles Blancho,Corinne Antoine,Sophie Caillard,Laurence Kessler,Moglie Le Quintrec,Orianne Villard,Dany Anglicheau,Matthias Büchler,Albane Brodin-Sartorius,Luc Frimat,Paolo Malvezzi,Sandrine Lablanche,Lionel Badet,Laure Esposito,Mikael Chetboun,Aghiles Hamroun,Julie Kerr-Conte,Thierry Berney,Marie-Christine Vantyghem,Marc Hazzan,François Pattou,TREPID-ABM study group,Mathieu Armanet,Céline Auxenfans,Benoit Averland,Pierre-Yves Benhamou,Ilies Benotmane,Ekaterine Berishvili,Dominique Bertrand,Stéphane Blanot,Sophie Borot,Julien Branchereau,Christophe Broca,Valérie Brunet,Pierre Cattan,Lucy Chaillous,Nicolas Chatauret,Gaelle Cheisson,Oriana Ciacio,Charlotte Colosio,Mathieu Cornuault,Emmanuel Cuellar,Guillaume Defortescu,Frédérique Defrance,Aurélie Deshayes,Gillian Divard,Thomas Domet,Jean-Pierre Duffas,Michelle Elias,Lionel Faivre,François Gaudez,Magali Giral,Sophie Girerd,Valery Gmyr,Philippe Gouin,Hélène Gregoire,Juliette Gueguen,Fadi Haidar,Thomas Hubert,Bénédicte Janbon,Marine Jeantet,Georges Karam,François Kerbaul,Clarisse Kerleau,Ilias Kounis,Caroline Laporte,Charlotte Laurent,Anne Lejay,Christophe Masset,Charles Mazeaud,Laëtitia Mokri,Karine Moreau,Emmanuel Morellon,Fabrice Muscari,Justine Nasone,Marc Padilla,Bastien Parier,Myriam Pastural,Quentin Perrier,Gabriella Pittau,Thomas Prudhomme,Eric Renard,Violeta Raverdy,António Sá Cunha,Chady Salloum,Emilien Seizilles De Mazancourt,Renaud Snanoudj,Oliver Thaunat,Rodolphe Thuret,Marc-Oliver Timsit,Florence Vachiery-Lahaye

Abstract:Background: Islet transplantation has been associated with better metabolic control and quality of life than insulin treatment alone, but direct evidence of its effect on hard clinical endpoints is scarce. We aimed to assess the effect of islet transplantation on patient-graft survival in kidney transplant recipients with type 1 diabetes. Methods: In this retrospective cohort study, we enrolled all patients with type 1 diabetes who received a kidney graft in France during the study period, identified from the CRISTAL nationwide registry. Non-inclusion criteria included recipients from transplant centres that never proposed islet transplantation during the study period, recipients with a functional pancreas throughout the follow-up duration, recipients with more than two kidney transplants, HLA-sensitised recipients, recipients with less than 1 year of follow-up after kidney transplantation, misclassified recipients with type 2 diabetes, recipients aged over 65 years, recipients of kidney grafts from Donation after Circulatory Death donors, recipient with HIV or hepatitis, recipients with cancer, and recipients of combined liver-kidney transplants. Patients who also received islet-after-kidney (IAK) transplantation were compared with controls who received kidney transplantation alone according to a 1:2 matching method based on time-dependent propensity scores, ensuring patients comparability at the time of islet transplantation. The primary outcome was patient-graft survival, a composite outcome defined by death, re-transplantation, or return to dialysis. Findings: Between Jan 1, 2000, and Dec 31, 2017, 2391 patients with type 1 diabetes were identified as having received a kidney transplant, 47 patients of whom also received an islet transplantation. 2002 patients were not eligible for islet transplantation and 62 were excluded due to missing data. 327 eligible recipients from 15 centres were included in the study dataset for the target trial emulation. 40 patients who received IAK transplantation were successfully matched to 80 patients who received kidney transplantation alone. 13 (33%) of 40 patients in the IAK transplantation group returned to dialysis or died, compared with 36 (45%) of 80 patients in the kidney transplantation alone group. We found a significant benefit of islet transplantation compared with kidney transplantation alone on patient-graft survival, with a hazard ratio (HR) of 0·44 (95% CI 0·23-0·88; p=0·022), mainly explained by a protective effect on the risk of death (HR 0·41, 0·13-0·91; p=0·042). There was no meaningful association between IAK and death-censored graft survival (0·73, 0·30-1·89; p=0·36). Interpretation: In kidney transplant recipients with type 1 diabetes, IAK transplantation was associated with a significantly better patient-graft survival compared with kidney transplantation alone, mainly due to a protective effect on the risk of death. These results potentially serve as compelling grounds for advocating wider access to islet transplantation in patients with type 1 diabetes undergoing kidney transplant, as reimbursement of islet transplantation is provided in few countries worldwide. Funding: Programme Hospitalier de la Recherche Clinique, Fondation pour la Recherche Medicale, and Fonds de Dotation Line Renaud-Loulou Gasté.

Phase 3 trial of human islet‐after‐kidney transplantation in type 1 diabetes

Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia

Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France

Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient

Allograft Islet Cell Transplantation and Postoperatively Modified Edmonton Protocol for 3 Cases of Type 1 Diabetes Mellitus

Islet Alone Versus Islet after Kidney Transplantation: Metabolic Outcomes and Islet Graft Survival

Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

A Strategy to Simultaneously Cure Type 1 Diabetes and Diabetic Nephropathy by Transplant of Composite Islet-Kidney Grafts

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Insulin independence following isolated islet transplantation and single islet infusions.

Islet Transplantation Using Donors after Brain and Cardiac Death: A Multicenter Clinical Trial in Japan

The Current Status of Allogenic Islet Cell Transplantation

The journey of islet cell transplantation and future development

1729-P: Role of ß-Cell Senescence in Islet Transplantation

Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes

Improvement of Massive Human Islet Isolation Techniques and the Evaluation of Isolated Human Islets

Islet Transplantation: Current Limitations and Challenges for Successful Outcomes

[Early Efficacy of Islet Transplantation in the Treatment of Adult Advanced Diabetes].

Significant expansion of the donor pool achieved by utilizing islets of variable quality in the production of allogeneic "Neo-Islets", 3-D organoids of Mesenchymal Stromal and islet cells, a novel immune-isolating biotherapy for Type I Diabetes

Assessment of long-term graft function following total pancreatectomy and autologous islet transplantation: the Leicester experience